Clinical Development Protein Expression Trials 
The Pharma Data
JUNE 7, 2023
3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. More than one million people are diagnosed with NSCLC at an advanced stage each year. 6 There are currently no TROP2 directed ADCs approved for the treatment of lung cancer. Rahway, NJ, USA), an anti-PD-1 therapy. “We
The Pharma Data
JULY 21, 2021
(NYSE: PFE), today announced that they have completed recruitment for the Phase 2 trial, VLA15-221, of Lyme disease vaccine candidate, VLA15. The trial builds on previous positive Phase 2 trials and includes both adult and pediatric participants with the aim to support acceleration of the vaccine candidate’s pediatric program.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
APRIL 26, 2022
Based on these new results, Valneva and Pfizer plan to proceed with inclusion of pediatric participants in their planned Phase 3 trial. The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected to be initiated in the third quarter of 2022, subject to regulatory approval.
The Pharma Data
MARCH 8, 2021
We are excited to be part of the Lyme disease vaccine development program with Valneva. Juan Carlos Jaramillo, MD, Chief Medical Officer of Valneva commented , “This trial initiation marks an important step in the development of VLA15 toward a potential licensure.
The Pharma Data
DECEMBER 8, 2020
Silverback’s lead candidate is currently in a Phase I trial in adults with HER2-expressing solid tumors. Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. Nuance Pharma .
The Pharma Data
JANUARY 15, 2021
In the DESTINY-Gastric01 trial, patients (n=126) in the Enhertu treatment arm had a 41% reduction in the risk of death versus patients (n=62) treated with chemotherapy (based on a hazard ratio [HR] of 0.59; 95% confidence interval [CI] 0.39-0.88; Regular approval by the U.S. months [95% CI 9.6-14.3] months [95% CI 6.9-10.7] with chemotherapy.
The Pharma Data
JANUARY 13, 2021
we determined the crystal structure of CD40-ligand 2 , developed a humanized version of our antibody (hu5c8, ruplizumab, or Antova®) and tested it in human trials for preventing organ transplant rejection and autoimmunity. CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function.
Expert insights. Personalized for you.
40 
Let's personalize your content